XenoPort (NASDAQ: XNPT) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
This is a breakdown of recent ratings for XenoPort and CoLucid Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CoLucid Pharmaceuticals has a consensus target price of $45.88, indicating a potential downside of 1.41%. Given CoLucid Pharmaceuticals’ higher probable upside, analysts clearly believe CoLucid Pharmaceuticals is more favorable than XenoPort.
Volatility and Risk
XenoPort has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, CoLucid Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
This table compares XenoPort and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares XenoPort and CoLucid Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
Institutional & Insider Ownership
64.2% of CoLucid Pharmaceuticals shares are held by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CoLucid Pharmaceuticals beats XenoPort on 6 of the 8 factors compared between the two stocks.
XenoPort Company Profile
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Receive News & Ratings for XenoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XenoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.